DE122004000048I1 - Neue chinuclidin-derivate und diese enthaltende pharmazeutische Pr{parate. - Google Patents

Neue chinuclidin-derivate und diese enthaltende pharmazeutische Pr{parate.

Info

Publication number
DE122004000048I1
DE122004000048I1 DE200412000048 DE122004000048C DE122004000048I1 DE 122004000048 I1 DE122004000048 I1 DE 122004000048I1 DE 200412000048 DE200412000048 DE 200412000048 DE 122004000048 C DE122004000048 C DE 122004000048C DE 122004000048 I1 DE122004000048 I1 DE 122004000048I1
Authority
DE
Germany
Prior art keywords
new
pharmaceutical preparations
preparations containing
diseases
chinuclidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE200412000048
Other languages
English (en)
Other versions
DE122004000048I2 (de
Inventor
Makoto Takeuchi
Ryo Naito
Masahiko Hayakawa
Yoshinori Okamoto
Yasuhiro Yonetoku
Ken Ikeda
Yasuo Isomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122004000048(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of DE122004000048I1 publication Critical patent/DE122004000048I1/de
Publication of DE122004000048I2 publication Critical patent/DE122004000048I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine
DE200412000048 1994-12-28 1995-12-27 Neue Chinuclidin-Derivate und diese enthaltende pharmazeutische Pr{parate Active DE122004000048I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (fr) 1994-12-28 1995-12-27 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Publications (2)

Publication Number Publication Date
DE122004000048I1 true DE122004000048I1 (de) 2005-04-21
DE122004000048I2 DE122004000048I2 (de) 2006-02-02

Family

ID=18194699

Family Applications (2)

Application Number Title Priority Date Filing Date
DE200412000048 Active DE122004000048I2 (de) 1994-12-28 1995-12-27 Neue Chinuclidin-Derivate und diese enthaltende pharmazeutische Pr{parate
DE69529844T Expired - Lifetime DE69529844T2 (de) 1994-12-28 1995-12-27 Neue chinuclidin-derivate und diese enthaltende pharmazeutische präparate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69529844T Expired - Lifetime DE69529844T2 (de) 1994-12-28 1995-12-27 Neue chinuclidin-derivate und diese enthaltende pharmazeutische präparate

Country Status (24)

Country Link
US (2) US6017927A (de)
EP (1) EP0801067B1 (de)
JP (1) JP3014457B2 (de)
KR (1) KR100386487B1 (de)
CN (1) CN1045601C (de)
AT (1) ATE233761T1 (de)
AU (1) AU695616B2 (de)
CA (1) CA2208839C (de)
DE (2) DE122004000048I2 (de)
DK (1) DK0801067T3 (de)
ES (1) ES2193208T3 (de)
FI (1) FI115631B (de)
FR (1) FR04C0032I2 (de)
HU (1) HU223778B1 (de)
LU (1) LU91133I9 (de)
MX (1) MX9704880A (de)
NL (1) NL300141I2 (de)
NO (4) NO2005012I1 (de)
NZ (1) NZ298144A (de)
PL (1) PL182344B1 (de)
PT (1) PT801067E (de)
RU (1) RU2143432C1 (de)
TW (1) TW305842B (de)
WO (1) WO1996020194A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
TR200400420T4 (tr) * 2000-06-27 2004-03-22 Laboratorios S.A.L.V.A.T., S.A. Arilalkilaminlerden türetilmiş karbamatlar.
IL156499A0 (en) * 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
JP4295985B2 (ja) 2000-12-28 2009-07-15 ラボラトリオス・アルミラル・ソシエダッド・アノニマ 新規なキヌクリジン誘導体およびそれを含む医薬組成物
CA2449922C (en) * 2001-07-10 2008-11-25 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for therapy of interstitial cystitis
IL162596A0 (en) * 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
MXPA04012070A (es) * 2002-06-07 2005-03-07 Yamanouchi Pharma Co Ltd Agente terapeutico para vejiga hiperactiva.
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
JP2006502985A (ja) 2002-07-08 2006-01-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体拮抗剤として有用な３，６−二置換アザビシクロ［３．１．０］ヘキサン誘導体
EP1546098B1 (de) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituierte azabicyclo [3.1.0]hexanderivate, die sich als muscarinrezeptorantagonisten eignen
EP1545508A4 (de) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ¬3.1.0 hexan-derivate als muscarinische rezeptor-antagonisten
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
BR0315784A (pt) * 2002-10-29 2005-09-20 Pharmacia & Upjohn Co Llc Compostos de amÈnio quaternário
EP1572648B1 (de) 2002-12-10 2008-07-09 Ranbaxy Laboratories, Ltd. 3,6-disubstituierte azabicyclo ¬3.1.0 -hexanderivative als antagonisten des muscarinrezeptors
BR0317606A (pt) * 2002-12-20 2005-11-29 Dynogen Pharmaceuticals Inc Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta)
US7465751B2 (en) 2002-12-23 2008-12-16 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
WO2004056811A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1492519B1 (de) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EP1618091A1 (de) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituierte azabicyclohexanderivate als antagonisten von muscarinrezeptoren
CA2521788A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (de) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. 3, 6-disubstitutierte azabicyclohexanderivate als muscarinrezeptorantagonisten
JP2006522787A (ja) 2003-04-11 2006-10-05 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
WO2005075474A1 (ja) * 2004-02-09 2005-08-18 Astellas Pharma Inc. コハク酸ソリフェナシン含有組成物
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
CA2560080A1 (en) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Solifenacin-containing composition
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
KR101270908B1 (ko) * 2004-03-25 2013-06-03 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1832288B1 (de) * 2004-12-27 2012-06-20 Astellas Pharma Inc. Stabile granulatförmige pharmazeutische zusammensetzung von solifenacin oder seinem salz
RU2397767C2 (ru) * 2004-12-27 2010-08-27 Астеллас Фарма Инк. Стабильная, состоящая из частиц фармацевтическая композиция, содержащая солифенацин или его соль
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1904495A2 (de) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Muscarin-rezeptor-antagonisten
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
CA2630846A1 (en) * 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Intermediates for preparing solifenacin
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
WO2008011462A2 (en) * 2006-07-19 2008-01-24 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2043639A2 (de) * 2006-07-24 2009-04-08 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung polymorpher formen von solifenacin-succinat
WO2008019103A2 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd Solifenacin base forms and preparation thereof
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008062282A2 (en) * 2006-11-22 2008-05-29 Medichem S.A. An improved process for the synthesis of solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
EP2142540A2 (de) * 2007-03-30 2010-01-13 Medichem S.A. Verbessertes verfahren zur synthese von solifenacin
EP2146693A2 (de) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin-zusammensetzungen
WO2009011844A1 (en) * 2007-07-13 2009-01-22 Teva Pharmaceutical Industries Ltd. Processes for solifenacin preparation
CN101754760A (zh) * 2007-07-20 2010-06-23 安斯泰来制药株式会社 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
EP2018850A1 (de) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit Solifenacin oder einem pharmazeutisch akzeptablen Salz daraus
DK2216021T3 (da) 2007-11-02 2012-11-05 Astellas Pharma Inc Farmaceutisk sammensætning til behandling af overaktiv blære
EP2229387A1 (de) * 2007-12-04 2010-09-22 Cadila Healthcare Limited Verfahren zur herstellung einer chemisch und chiral reinen solifenacinbase und ihrer salze
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP3178477A1 (de) 2008-03-27 2017-06-14 Chase Pharmaceuticals Corporation Kombination von nspacha (periphärem anticholinergen wirkstoff) wie solifenacin und einem achei (acetylcholinesterase inhibitor) wie donepezil in der verwendung zur behandlung von demenz
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
WO2010012459A2 (en) * 2008-07-29 2010-02-04 Krka, D.D., Novo Mesto A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EP2181707A1 (de) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Kombinierte Verwendung eines alpha-adrenergischen Rezeptorantagonisten und eines Antimuskarinmittels
NZ594311A (en) 2009-02-04 2013-05-31 Astellas Pharma Inc Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
US8283470B2 (en) 2009-03-09 2012-10-09 Megafine Pharma(P) Ltd. Method for the preparation of solifenacin and intermediate thereof
JP4816828B2 (ja) 2009-03-30 2011-11-16 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (en) * 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
WO2011125763A1 (ja) 2010-03-31 2011-10-13 小野薬品工業株式会社 手足症候群の予防および／または治療剤
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
EP2572717B1 (de) 2010-05-19 2016-06-15 Astellas Pharma Inc. Pharmazeutische zusammensetzung mit solifenacin
WO2012001481A1 (en) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Novel process for the preparation of solifenacin succinate
WO2012004264A1 (en) 2010-07-05 2012-01-12 Ragactives, S.L.U. Solifenacin salts
WO2012062916A1 (de) 2010-11-11 2012-05-18 Hexal Ag Kristallines solifenacin-succinat
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
EP2706997B1 (de) 2011-05-10 2019-03-27 TheraVida, Inc. Kombinationen aus solifenacin und pilocarpin zur behandlung von hyperaktiver blase
CN103702997A (zh) 2011-06-22 2014-04-02 伊索凯姆公司 索非那新及其盐的制备方法
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
WO2014005601A1 (en) 2012-07-02 2014-01-09 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
SG11201501415RA (en) 2012-08-31 2015-05-28 Astellas Pharma Inc Orally administered medical composition
WO2014039627A1 (en) 2012-09-05 2014-03-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
EP2928890B1 (de) * 2012-12-06 2018-02-28 Chiesi Farmaceutici S.p.A. Verbindungen mit muskarinrezeptoragonisten- und beta2-adrenergen-rezeptoragonistenaktivität
EP2778167A1 (de) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stabile pharmazeutische Zubereitung enthaltend Solifenacin oder deren pharmazeutisch verträgliches Salz
JP6218940B2 (ja) * 2013-07-13 2017-10-25 ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド キニン系化合物、その光学異性体及びその製造方法と医薬用途
EP3139924A4 (de) 2014-05-06 2018-03-07 Anthony G. Visco Verfahren zur behandlung oder prävention von vorzeitigen wehen
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
US20210163471A1 (en) * 2017-12-12 2021-06-03 Arkuda Therapeutics Progranulin modulators and methods of using the same
CA3139561A1 (en) 2019-06-12 2020-12-17 Arkuda Therapeutics Progranulin modulators and methods of using the same
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247266B1 (de) * 1986-01-07 1993-03-10 Beecham Group Plc Indolderivate mit einer azabicyclischen Seitenkette, Verfahren zu ihrer Herstellung, Zwischenprodukte und pharmazeutische Zusammensetzungen
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
ATE339121T1 (de) * 2002-11-27 2006-10-15 Selmac S R L Vorrichtung zum positionieren und spannen geformter teile und damit ausgerüstete maschine

Also Published As

Publication number Publication date
CA2208839A1 (en) 1996-07-04
HU223778B1 (hu) 2005-01-28
NO2017055I2 (no) 2017-11-06
AU4355396A (en) 1996-07-19
FI115631B (fi) 2005-06-15
HUT77006A (hu) 1998-03-02
CA2208839C (en) 2006-01-31
AU695616B2 (en) 1998-08-20
NO318026B1 (no) 2005-01-24
NO973027L (no) 1997-08-28
US6174896B1 (en) 2001-01-16
CN1171109A (zh) 1998-01-21
ATE233761T1 (de) 2003-03-15
NL300141I1 (nl) 2004-04-01
FI972775A0 (fi) 1997-06-27
DK0801067T3 (da) 2003-06-30
LU91133I2 (fr) 2005-03-29
US6017927A (en) 2000-01-25
TW305842B (de) 1997-05-21
FR04C0032I2 (fr) 2005-10-21
DE122004000048I2 (de) 2006-02-02
EP0801067A4 (de) 1998-03-11
EP0801067B1 (de) 2003-03-05
NO2005016I1 (no) 2005-08-29
KR100386487B1 (ko) 2003-09-26
PL321019A1 (en) 1997-11-24
NO2005016I2 (no) 2008-02-11
NL300141I2 (nl) 2004-04-01
KR987000303A (ko) 1998-03-30
NO2017055I1 (no) 2017-11-06
FI972775A (fi) 1997-08-22
DE69529844T2 (de) 2004-03-04
NO2005012I1 (no) 2005-06-06
EP0801067A1 (de) 1997-10-15
LU91133I9 (en) 2018-08-01
JPH09508401A (ja) 1997-08-26
DE69529844D1 (de) 2003-04-10
RU2143432C1 (ru) 1999-12-27
CN1045601C (zh) 1999-10-13
ES2193208T3 (es) 2003-11-01
JP3014457B2 (ja) 2000-02-28
NO973027D0 (no) 1997-06-27
FR04C0032I1 (de) 2005-02-11
WO1996020194A1 (fr) 1996-07-04
MX9704880A (es) 1997-10-31
PL182344B1 (pl) 2001-12-31
NZ298144A (en) 1998-04-27
PT801067E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
DE122004000048I1 (de) Neue chinuclidin-derivate und diese enthaltende pharmazeutische Pr{parate.
ATE170510T1 (de) 3-(hydroxybenzylidenyl)-indolin-2-one und diese enthaltende arzneimittel
DE69111138T2 (de) Heterocyclische Verbindungen mit antiemetischer und Migräne unterdrückender Wirkung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen.
NO942953L (no) 11-benzaldoksimestradienderivater, fremgangsmåte for deres fremstilling smat legemddel inneholdende slike
ATE110071T1 (de) Pyridazinon-derivate und diese enthaltende pharmazeutische zubereitungen.
EP1329218A4 (de) Wirkstoffe zur vorbeugung und behandlung portaler hypertonie
DE69206787D1 (de) 4-[(2-Benzothiazolyl)Methylamino]-alpha-(3,4-Difluorphenoxy)methyl-1-piperidenethanol
FI911138A (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
DE69300318D1 (de) Flavonderivate.
DK0580503T3 (da) Aminoalkylchromoner, fremgangsmåde til fremstilling heraf samt midler indeholdende disse
NO903291D0 (no) Renin-hemmende aminooligohydroksy-derivater.